Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

Dominick E. Shaw, Ana R. Sousa, Stephen J. Fowler, Louise J. Fleming, Graham Roberts, Julie Corfield, Ioannis Pandis, Aruna T. Bansal, Elisabeth H. Bel, Charles Auffray, Chris H. Compton, Hans Bisgaard, Enrica Bucchioni, Massimo Caruso, Pascal Chanez, Barbro Dahlén, Sven Erik Dahlen, Kerry Dyson, Urs Frey, Thomas GeiserMaria Gerhardsson De Verdier, David Gibeon, Yi Ke Guo, Simone Hashimoto, Gunilla Hedlin, Elizabeth Jeyasingham, Pieter Paul W. Hekking, Tim Higenbottam, Ildikó Horváth, Alan J. Knox, Norbert Krug, Veit J. Erpenbeck, Lars X. Larsson, Nikos Lazarinis, John G. Matthews, Roelinde Middelveld, Paolo Montuschi, Jacek Musial, David Myles, Laurie Pahus, Thomas Sandström, Wolfgang Seibold, Florian Singer, Karin Strandberg, Jorgen Vestbo, Nadja Vissing, Christophe Von Garnier, Ian M. Adcock, Scott Wagers, Anthony Rowe, Peter Howarth, Ariane H. Wagener, Ratko Djukanovic, Peter J. Sterk, Kian Fan Chung

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach. This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements. Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids. Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.

Original languageEnglish
Pages (from-to)1308-1321
Number of pages14
JournalEuropean Respiratory Journal
Volume46
Issue number5
DOIs
Publication statusPublished - Nov 1 2015

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort'. Together they form a unique fingerprint.

  • Cite this

    Shaw, D. E., Sousa, A. R., Fowler, S. J., Fleming, L. J., Roberts, G., Corfield, J., Pandis, I., Bansal, A. T., Bel, E. H., Auffray, C., Compton, C. H., Bisgaard, H., Bucchioni, E., Caruso, M., Chanez, P., Dahlén, B., Dahlen, S. E., Dyson, K., Frey, U., ... Chung, K. F. (2015). Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. European Respiratory Journal, 46(5), 1308-1321. https://doi.org/10.1183/13993003.00779-2015